FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis. PMID 40365708 · Br J Dermatol · 2025-Aug-18 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer. PMID 40819868 · BMJ Open · 2025-Aug-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Multiparametric MRI for local staging in patients with suspected muscle-invasive bladder cancer: study protocol for a multicentre, non-inferiority randomised controlled trial (the BladParadigm study). PMID 40819867 · BMJ Open · 2025-Aug-16 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial. PMID 40819029 · BMC Cancer · 2025-Aug-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. PMID 40818852 · Lancet · 2025-Aug-16 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial. PMID 40817977 · J Neurol · 2025-Aug-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Diet and physical activity in colorectal cancer patients: A research protocol of a randomized controlled study. PMID 40837756 · World J Gastrointest Oncol · 2025-Aug-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of PD-1 inhibitors in combination with chemotherapy as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction cancer across subgroups: A comprehensive systematic review and meta-analysis. PMID 40826733 · Medicine (Baltimore) · 2025-Aug-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| ACT 2 Clinical Trial Design: Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living with HIV. PMID 40832398 · medRxiv · 2025-Aug-14 The record describes a Phase 2b feasibility trial protocol for cervical precancer treatment in HIV-positive women. It is a randomized trial with a drug intervention (5-fluorouracil), but it is not a Phase III/IIIb or Phase II/III trial, it is not an original result report (it is a design/protocol paper), and the primary/secondary outcomes are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS) but rather acceptability, feasibility, and histological/HPV clearance at fixed time points. Therefore, it does not meet the required criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of Qingbu Weijing decoction in treatment stable bronchiectasis: study protocol for a multicenter, double- blind, randomized and placebo-controlled trial. PMID 40813996 · BMC Complement Med Ther · 2025-Aug-14 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Patient-Centered Risk Prediction, Prevention, and Intervention Platform (TIMELY) to Support the Continuum of Care in Coronary Artery Disease Using eHealth and Artificial Intelligence: Protocol for a Randomized Controlled Trial. PMID 40812736 · JMIR Res Protoc · 2025-Aug-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Hematological toxicity of parp inhibitors in solid tumors: a systematic review and safety meta-analysis. PMID 40804462 · Cancer Metastasis Rev · 2025-Aug-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. PMID 40544433 · N Engl J Med · 2025-Aug-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. PMID 40544432 · N Engl J Med · 2025-Aug-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Addition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial. PMID 40499144 · Clin Cancer Res · 2025-Aug-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparative analysis of the use of Community Health Workers while deploying the Attractive Targeted Sugar Bait (ATSB) for malaria control in Western Province, Zambia. PMID 40804418 · Malar J · 2025-Aug-13 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Textbook outcome in low rectal cancer patients undergoing laparoscopic or open surgery: 3-year results from the multicentric LASRE Trial. PMID 40804342 · Int J Colorectal Dis · 2025-Aug-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Interventions for anal canal intraepithelial neoplasia. PMID 40801169 · Cochrane Database Syst Rev · 2025-Aug-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201. PMID 40609265 · Vaccine · 2025-Aug-13 The study is a Phase III randomized trial of a drug intervention (vaccine) in oncology (preventing cancer precursor), but it is a protocol publication without results. Furthermore, the primary endpoint (incidence of persistent oral HPV infection) is an infection incidence endpoint, not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II/III randomized immunogenicity and safety study of a Brazilian meningococcal serogroup B vaccine in children. PMID 40494223 · Vaccine · 2025-Aug-13 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). PMID 40479932 · Vaccine · 2025-Aug-13 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, double-blind, positive control, phase III clinical trial. PMID 40479926 · Vaccine · 2025-Aug-13 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of exercise interventions on cardiotoxicity in patients with breast cancer undergoing chemotherapy: a study protocol for a quasi-randomised controlled trial. PMID 40803741 · BMJ Open · 2025-Aug-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. PMID 40792645 · Ann Surg · 2025-Aug-12 The study is an oncology RCT with drug interventions, but its primary endpoint is the incidence of major surgical complications, which is a binary safety/morbidity outcome, not a time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Telemedicine follow-up for pre-malignant and malignant glottic lesions: a randomised controlled trial study protocol comparing care close to home versus standard of care. PMID 40791158 · Acta Oncol · 2025-Aug-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B. PMID 40769675 · J Am Coll Cardiol · 2025-Aug-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy. PMID 40769673 · J Am Coll Cardiol · 2025-Aug-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Noncontrast CT vs CT Perfusion Imaging in Patients With Basilar Artery Occlusion: Analysis of the ATTENTION and ATTENTION IA Trials. PMID 40674670 · Neurology · 2025-Aug-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial. PMID 40249856 · Blood Adv · 2025-Aug-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy. PMID 40790765 · Breast Cancer Res · 2025-Aug-11 The study meets all other criteria but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided record. Eligibility requires explicit confirmation of a definitive trial phase. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A randomized trial to evaluate the pharmacokinetics, pharmacodynamics, and safety of vadadustat in patients with anemia associated with chronic kidney disease receiving hemodialysis. PMID 40790188 · BMC Nephrol · 2025-Aug-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Assessing participants' experiences with the COVID-19 symptom diary in a clinical trial. PMID 40788441 · J Patient Rep Outcomes · 2025-Aug-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Neoadjuvant Chemotherapy with or without Immune Checkpoint Inhibitors for Resectable Esophageal Squamous Cell Carcinoma: a Meta-analysis of Randomized Controlled Trials. PMID 40788432 · J Gastrointest Cancer · 2025-Aug-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies. PMID 40787733 · Cochrane Database Syst Rev · 2025-Aug-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Duplex ultrasound after endo revascularisation (DUSTER): protocol for a randomised controlled feasibility trial. PMID 40784780 · BMJ Open · 2025-Aug-10 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). PMID 40561410 · J Clin Oncol · 2025-Aug-10 The record is a published erratum for a Phase III trial. While it pertains to an oncology, randomized, drug-intervention study, it is not an original result report. The erratum itself does not provide the primary efficacy data (time-to-event outcomes) needed for inclusion. The deterministic review correctly identified a lack of time-to-event signal. |
H
|
仅历史库存 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial). PMID 40554738 · J Clin Oncol · 2025-Aug-10 The study is a randomized oncology trial with time-to-event endpoints, but it compares two surgical/procedural interventions (surgery vs. radiofrequency ablation) and does not involve a drug-containing intervention, which is a required criterion for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial. PMID 40540704 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study. PMID 40532125 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer. PMID 40493877 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer. PMID 40424564 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial. PMID 40233286 · J Clin Oncol · 2025-Aug-10 The record is excluded because it does not meet two key criteria for inclusion: 1) it is a non-drug intervention study (radiotherapy dose comparison, not a drug-containing arm), and 2) it does not have a primary or key secondary time-to-event efficacy endpoint (the primary endpoint is a quality-of-life score, and the secondary is a cumulative incidence, not a time-to-event analysis). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21). PMID 40783751 · BMC Cancer · 2025-Aug-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial. PMID 40783722 · BMC Cancer · 2025-Aug-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparing the effectiveness of implementation strategies to improve liver and colon cancer screening for Veterans: protocol for a large cluster-randomized implementation study. PMID 40783525 · Implement Sci · 2025-Aug-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Phase II single vs hypofractionated irradiation for timely access to partial breast radiotherapy (SHIFT-PB). PMID 40781619 · BMC Cancer · 2025-Aug-08 The record describes a Phase II randomized controlled trial protocol for a radiation therapy fractionation study, not a report of results from a Phase III/IIIb or definitive Phase II/III randomized trial with drug intervention and time-to-event efficacy endpoints. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Can preoperative CT angiography and three-dimensional reconstruction of the mesenteric artery of the colon improve laparoscopic colectomy and postoperative rehabilitation in patients with colon cancer? A pilot randomized control study. PMID 40779208 · Int J Colorectal Dis · 2025-Aug-08 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| [Interpretation and implications of the phase Ⅲ KEYNOTE-689 trial in head and neck squamous cell carcinoma]. PMID 40890052 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2025-Aug-07 The record appears to be a commentary or interpretation article about a Phase III trial, not the original trial report with primary or secondary efficacy results. Without an abstract or clear evidence of reporting trial outcomes, it cannot be considered an eligible primary result report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of nurse-led intervention programs based on spiritual care on the resilience and death anxiety in parents of children and adolescents with cancer, a randomized clinical trial. PMID 40775798 · BMC Psychol · 2025-Aug-07 Study is a randomized trial in an oncology context but evaluates a non-drug nursing intervention (spiritual care) with psychological endpoints, lacking any drug intervention or time-to-event efficacy endpoint as defined. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial. PMID 40775020 · Nat Commun · 2025-Aug-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |